Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations.
| Autor: | Bhat SZ; Department of Endocrinology, Diabetes and Metabolism, Johns Hopkins Hospital, Baltimore, MD, USA., Dobs AS; Department of Endocrinology, Diabetes and Metabolism, Johns Hopkins Hospital, Baltimore, MD, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | TouchREVIEWS in endocrinology [touchREV Endocrinol] 2022 Nov; Vol. 18 (2), pp. 133-140. Date of Electronic Publication: 2022 Aug 24. |
| DOI: | 10.17925/EE.2022.18.2.133 |
| Abstrakt: | Male hypogonadism affects 10-30% of the male population and is often under-recognized and under-treated. Different replacement formulations exist, each with specific benefits and limitations. These replacements include gels, patches and short- and long-acting injectables. JATENZO® (oral testosterone undecanoate; Clarus Therapeutics Inc., Northbrook, IL, US) is the first oral formulation of testosterone approved by the US Food and Drug Administration. TLANDO® (oral testosterone undecanoate; Lipocine Inc., Salt Lake City, UT, US), another oral testosterone formulation, has also recently been approved by the US Food and Drug Administration. Based on unique chemistry using a self-emulsifying drug delivery system and lymphatic absorption, JATENZO and TLANDO address some of the limitations of other dosing routes while providing a safe option without evidence of liver dysfunction. This review discusses various testosterone treatment options, focusing on the role and pharmacokinetics of the new oral formulations. Competing Interests: Disclosure: Salman Z Bhat and Adrian S Dobs have no financial or non-financial relationships or activities to declare in relation to this article. (© Touch Medical Media 2022.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|